VistaGen Therapeutics Inc., a clinical-stage firm that specializes in biopharmaceutical products, is currently focused on developing and commercializing a range of drugs that aim to address anxiety, depression, and central nervous system disorders. One of the company's most exciting candidates is PH94B, a neuroactive nasal spray that works rapidly to alleviate anxiety symptoms in adults with social anxiety disorder. PH94B also has potential for use with other anxiety-related disorders such as postpartum anxiety, adjustment disorder with anxiety, and panic disorders. Meanwhile, PH10 is a rapid-onset neuroactive nasal spray preparing for Phase 2B clinical trials, acting as a standalone treatment for major depressive disorder. Finally, AV-101, an oral N-methyl-D-aspartate receptor antagonist, is in development in tandem with oral probenecid as a possible treatment route for various disorders including MDD, neuropathic pain, suicidal ideation, and levodopa-induced dyskinesia. VistaGen operates with the aid of various agreements, including a contract research and development agreement with Cato Research Ltd., a license agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Based in South San Francisco, California, VistaGen Therapeutics, Inc., began operations in 1998.